Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Anti-cytokine therapeutic antibodies have been demonstrated to be effective in the treatment of several auto-immune disorders. However, The problems in antibody manufacture and the immunogenicity caused by multiple doses of antibodies inspire people to use auto-cytokine as immunogen to induce anti-cytokine antibodies. Nevertheless, the tolerance for inducing immune response against self-antigen has hindered the wide application of the strategy. To overcome the tolerance, here we proposed a strategy using the inter-species cytokine as immunogen for active immunization (TISCAI) to induce anti-cytokine antibody. As a proof of concept, an inter-species cytokine RANKL was successfully used as immunogen to induce anti-RANKL immune response. Furthermore, to prevent undesirable side-effects, the human RANKL was mutated based on the crystal structure of the complex of human RANKL and its rodent counterpart receptor RANK. We found, the antibodies produced blocked the osteoclast development in vitro and osteoporosis in OVX rat models. The results demonstrated this strategy adopted is very useful for general anti-cytokine immunotherapy for different diseases settings.

Original publication

DOI

10.1038/srep14150

Type

Journal article

Journal

Sci Rep

Publication Date

28/09/2015

Volume

5

Keywords

Animals, Antibodies, Autoantigens, Bone Resorption, Cell Differentiation, Disease Models, Animal, Humans, Immunization, Immunotherapy, Mice, Models, Molecular, Osteoclasts, Osteoporosis, Ovariectomy, Protein Binding, Protein Conformation, RANK Ligand, Rats, Receptor Activator of Nuclear Factor-kappa B, Vaccines, X-Ray Microtomography